Core Viewpoint - Tumor immunotherapy, particularly immune checkpoint blockade (ICB) targeting the PD-1/PD-L1 pathway, shows promise in treating advanced cancers but is limited by insufficient response rates. Recent findings suggest that Gasdermin D-mediated pyroptosis can trigger a robust systemic immune response, with only 15% of pyroptotic tumor cells capable of eliminating the entire tumor, presenting a new strategy for enhancing anti-tumor immunity [2][3][10]. Summary by Sections Research Development - A new self-luminous photodynamic therapy system, CC@PDC, has been developed to efficiently activate pyroptosis and stimulate anti-tumor immunity. This system, when used in conjunction with anti-PD-L1 antibodies, demonstrates superior anti-tumor and immune effects, offering a novel strategy for cancer treatment [3][10]. Mechanism and Composition - The CC@PDC system is designed with efficient resonance energy transfer, effective generation of singlet oxygen (1 O₂), and strong pyroptosis induction capabilities. It consists of amphiphilic porphyrin lipids, camptothecin derivatives, and a targeted assembly that encapsulates oleic acid-modified calcium peroxide and a specific compound to enhance its efficacy in acidic tumor microenvironments [7][10]. Key Findings - The study highlights that the camptothecin-enhanced self-luminous photodynamic chemotherapy can synergistically induce tumor cell pyroptosis and, when combined with anti-PD-L1 antibodies, significantly enhances the anti-tumor immune response, providing a promising new approach for cancer therapy [10][11].

Core Viewpoint - The clinical study published in the journal "Med" demonstrates the effectiveness and safety of a new photodynamic therapy, APL-1702, for treating high-grade squamous intraepithelial lesions (HSIL) of the cervix, marking a significant advancement in cervical cancer prevention [1][2] Group 1: Study Overview - The study is a rigorous multi-center, randomized, double-blind trial conducted globally, confirming the efficacy and safety of APL-1702 [1] - A total of 402 patients with confirmed high-grade squamous intraepithelial lesions (CIN2 and CIN3) were enrolled in the trial, which was conducted across 61 international centers [2] Group 2: Treatment Methodology - APL-1702 utilizes a novel approach where a photosensitizer is absorbed by HPV-infected cells, followed by LED light exposure to induce cell death, overcoming limitations of previous intravenous photosensitizers [2] - The treatment involves a 2:1 random allocation to either the APL-1702 treatment group or a placebo control group, using a local application of 5% aminolevulinic acid and specific wavelength light [2] Group 3: Clinical Implications - The non-invasive nature of this therapy better preserves cervical structure and physiological function, providing a safer option for women that effectively controls lesions while maximizing future pregnancy safety [2]

Core Viewpoint - The article discusses a novel approach to overcoming tumor resistance to traditional therapies through a CRISPR-based nano-vaccine (AVAX) that targets the HO-1 gene, enhancing the efficacy of photodynamic therapy and activating anti-tumor immunity [3][4]. Group 1: Research Findings - The study published in Nature Biomedical Engineering presents a CRISPR-Cas9 based nano-vaccine (AVAX) that effectively knocks out the HO-1 gene, reversing tumor cell resistance to reactive oxygen species (ROS) and significantly improving photodynamic therapy outcomes [3][4]. - AVAX demonstrated a 20.15% gene editing efficiency for HO-1 in B16F10 melanoma and LL/2 lung cancer models, leading to enhanced photodynamic therapy efficacy and the induction of an autologous vaccine effect [6][8]. - The combination of AVAX and photodynamic therapy achieved a tumor suppression rate of 93%, with edited ROS-sensitive phenotypes being heritable in progeny tumor cells [8]. Group 2: Mechanism and Efficacy - The AVAX platform utilizes a core-shell self-assembly structure for efficient delivery of the CRISPR-Cas9 system, targeting the ROS resistance gene HO-1 [6]. - When combined with PD-L1 antibodies, 50% of tumor-bearing mice exhibited complete tumor regression, with survival extending beyond 50 days [8]. - The treatment led to a significant increase in CD8 T and CD4 T cell infiltration in tumors, while reducing immunosuppressive myeloid cells [9]. Group 3: Safety and Implications - Safety assessments indicated that the nano-vaccine did not exhibit significant toxicity to major organs, and no off-target editing was detected in immune cells [9]. - This research integrates gene editing with immune activation, achieving a strategy of "enhanced sensitivity and reversal of resistance" in tumor treatment [9].